Literature DB >> 6541804

Targeting of liposomes: monoclonal antibodies coupled to phospholipid vesicles provide selective transfer of trapped reagents into cultured cells.

L Guidoni, C J O'Hara, G B Price, J Shuster, A Fuks.   

Abstract

Monoclonal antibodies were incorporated in small unilamellar vesicles by means of ultrasonic irradiation. In order to increase the incorporation efficiency, the immunoglobulins were previously treated at low pH (pH 2), following recent suggestions on the existence of a lipid soluble conformational isomer for serum IgG. The lipid to protein ratios obtained were comparable to the values obtained by other authors using covalent coupling of the antibody to the lipid matrix. Liposome-incorporated monoclonal antibodies directed towards carcinoembryonic antigen (CEA) provided increased transfer of the fluorescent dye carboxyfluorescein from liposomes into cultured human colon carcinoma cells. Another independent experiment was performed on the drug-resistant CHO cell line B30, using a monoclonal antibody to a cell surface marker of drug resistance. Selective liposome mediate drug killing was observed following incubation of the cells with liposomes containing the antitumor agent drug, daunorubicin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6541804

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  Echogenic liposome compositions for increased retention of ultrasound reflectivity at physiologic temperature.

Authors:  Kyle D Buchanan; Shaoling Huang; Hyunggun Kim; Robert C Macdonald; David D McPherson
Journal:  J Pharm Sci       Date:  2008-06       Impact factor: 3.534

Review 2.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.

Authors:  Claire Vanpouille-Box; François Hindré
Journal:  Front Oncol       Date:  2012-10-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.